Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.50 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | PDE4A | P27815 | 7/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23047395 | 0.87 | PDGFRB (0.47) | PDGFRBPDGFRATRPC6PDE4BPDE4A | |
| SCHEMBL21045780 | 0.77 | TRPC6 (0.55) | PDGFRBPDGFRATRPC6PDE4BPDE4A | |
| SCHEMBL21045621 | 0.76 | TRPC6 (0.54) | PDGFRBPDGFRATRPC6PDE4BPDE4A | |
| SCHEMBL21045697 | 0.75 | PDE4B (0.55) | PDGFRBPDGFRATRPC6PDE4BPDE4A | |
| SCHEMBL23426471 | 0.75 | TRPC6 (0.46) | PDGFRBPDGFRATRPC6 | |
| SCHEMBL21045661 | 0.74 | PDE4A (0.54) | PDGFRBPDGFRATRPC6PDE4BPDE4A | |
| SCHEMBL71175 | 0.74 | PDE4A (0.58) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL71378 | 0.72 | PDE4A (0.52) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL23427133 | 0.72 | TRPC6 (0.39) | TRPC6PDE4APDE4DKMT2AGAK | |
| SCHEMBL24610478 | 0.72 | TSHR (0.41) | TRPC6PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-10800757-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169167-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | PDGFRB 1892/4885PDGFRA 1678/4885TRPC6 1/4885 |
| US-10800757-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | PDGFRB 1892/4885PDGFRA 1678/4885TRPC6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.